Bioengineered Lysozyme Reduces Bacterial Burden and Inflammation in a Murine Model of Mucoid Pseudomonas aeruginosa Lung Infection

Authors

Charlotte C. Teneback, University of Vermont
Thomas C. Scanlon, Dartmouth College
Matthew J. Wargo, University of Vermont
Jenna L. Bement, University of Vermont
Karl E. Griswold, Dartmouth CollegeFollow
Laurie W. Leclair, University of Vermont

Document Type

Article

Publication Date

8-26-2013

Publication Title

Antimicrobial Agents and Chemotherapy

Department

Thayer School of Engineering

Abstract

The spread of drug-resistant bacterial pathogens is a growing global concern and has prompted an effort to explore potential adjuvant and alternative therapies derived from nature's repertoire of bactericidal proteins and peptides. In humans, the airway surface liquid layer is a rich source of antibiotics, and lysozyme represents one of the most abundant and effective antimicrobial components of airway secretions. Human lysozyme is active against both Gram-positive and Gram-negative bacteria, ac

DOI

10.1128/AAC.00500-13

Original Citation

Teneback CC, Scanlon TC, Wargo MJ, Bement JL, Griswold KE, Leclair LW. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother. 2013 Nov;57(11):5559-64. doi: 10.1128/AAC.00500-13. Epub 2013 Aug 26. PMID: 23979752; PMCID: PMC3811238.

Dartmouth Digital Commons Citation

Teneback, Charlotte C.; Scanlon, Thomas C.; Wargo, Matthew J.; Bement, Jenna L.; Griswold, Karl E.; and Leclair, Laurie W., "Bioengineered Lysozyme Reduces Bacterial Burden and Inflammation in a Murine Model of Mucoid Pseudomonas aeruginosa Lung Infection" (2013). Dartmouth Scholarship. 468.
https://digitalcommons.dartmouth.edu/facoa/468